Instructions for Credit — This activity is accredited for 1.25 continuing education credits for nurse practitioners, nurses, and social workers. Participants must attend the free webinar in its entirety, submit the online evaluation form and complete and submit the online post-test with a passing score of 70% to earn credit. Once submitted, the certificate will be automatically generated as a PDF online.
Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or ndane@mlicme.org.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
Target Audience — Nurse practitioners, nurses and oncology social workers involved in the care of patients with multiply myeloma (MM).
Course Content Level for Social Workers — Intermediate and Advanced
Format: Non-interactive recorded webinar
| Learning Objectives — At the conclusion of this program, participants will be able to: | |
| • | Describe an overview of multiple myeloma (MM) |
| • | Identify tests used to diagnose disease and monitor treatment of MM |
| • | Explain the overarching goals of treatment for MM |
| • | Explain approved and emerging treatment options for MM, including stem cell transplantation, and the role of clinical trials |
| • | Describe strategies to manage treatment side effects as well as potential long-term and late effects of treatments for MM |
| • | Describe the roles of the pharmacist, the nurse and the social worker in treating patients with MM |
Provider — This activity is provided by The Leukemia & Lymphoma Society.
Continuing Education for Nurse Practitioners, Nurses, and Social Workers
Nurse Practitioner Credit Designation
This activity is approved for 1.25 contact hours of continuing education (which includes .66 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20064303. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.25 continuing education contact hours through the California Board of Registered Nursing.
Social Worker Designation
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. LLS maintains responsibility for this course. ACE provider approval period: 12/10/2020-12/10/2023. Social workers completing this course receive 1.25 continuing education credits.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive 1.25 CE clinical contact hours for this activity.
To view system requirements please go to https://llsce.org/system-requirements
For questions, grievances, or assistance with special needs (physical, etc.) please contact us atProfEducation@LLS.org .
Disclosure of Conflicts of Interest — All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
Faculty Disclosures
Sagar Lonial, MD, has nothing to disclose.
Kathryn Maples, PharmD, BCOP, has nothing to disclose.
Charise Gleason, has nothing to disclose.
Content/Peer Reviewer Disclosures
Felicia Williams, DNP, AOCNP, has nothing to disclose.
Disclaimer — All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
| Estimated time to complete activity: 1.25 hours |
| Date of initial release: June 5, 2020 |
| Valid for CE credit through: July 31, 2021 |
 |
|
Sagar Lonial, MD, is the Department Chair for Hematology and Medical Oncology at Emory University, and is the myeloma editor for Clinical Lymphoma and Myeloma and on the editorial board for the Journal of Clinical Oncology. He is also an ad hoc reviewer for Blood, Cancer Research, Clinical Cancer Research, Haematologica, Leukemia, and other journals. He has authored or co-authored over 200 papers and abstracts. He serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the board of directors for the International Myeloma Society and on the scientific Advisory Board for the International Myeloma Foundation.
Dr. Lonial has worked in the field of immunotherapy and cancer, and has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. Dr. Lonial’s previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway and the role of 14-3-3 in proteasome function.
 |
|
Kathryn Maples, PharmD, BCOP, received her Doctor of Pharmacy from the University of Georgia College of Pharmacy in 2015. She then completed her ASHP-accredited PGY1 Pharmacy Practice Residency and PGY2 Oncology Pharmacy Residency at Virginia Commonwealth University Health in Richmond, VA. Dr. Maples began her career as a clinical pharmacy specialist within the lymphoma/myeloma group at Memorial Sloan Kettering Cancer Center in August 2017, and joined Emory Winship Cancer Institute as a myeloma clinical specialist in June 2019. She is board certified in oncology pharmacy and her professional interests include clinical research in multiple myeloma, hematopoietic cell transplantation, and survivorship support.
 |
|
Charise Gleason, MSN, NP-BC, AOCNP®, is a nurse practitioner in the Multiple Myeloma program at the Emory Winship Cancer Institute in Atlanta. She has been at Emory since 1998, when she started as a hematology/oncology nurse, and she joined the BMT program as a nurse practitioner in 2003. She is also adjunct faculty at the Nell Hodgson Woodruff School of Nursing at Emory University and chief Advanced Practice Provider for Winship Cancer Institute of Emory University. She earned both her bachelor’s and master’s degrees from Emory University, and holds an advanced oncology certification through the ONCC.
Ms. Gleason has been an active presenter and educator on the topics of multiple myeloma, plasma cell dyscrasias, survivorship, and side effect management, and is an active participant on the International Myeloma Foundation Nurse Leadership Board. She is also active in clinical research and has authored or co-authored many publications, including book chapters, abstracts, articles for nursing journals, and scientific publications.
Resources for HCPs
Online & In-person free CME & CE courses: www.LLS.org/CE
Treating Blood Cancers podcasts: www.LLS.org/HCPpodcast
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: LLS.org/Research
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Resources for Patients
MM Specific Resources – www.LLS.org/MM
Free Information Booklets: www.LLS.org/Booklets
Telephone/Web Education Programs: www.LLS.org/Programs
Videos: www.LLS.org/Educationvideos
Podcasts: www.LLS.org/LLS-podcast
Support Resources : www.LLS.org/Support
- Financial Assistance
- Co-Pay
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
Information Resource Specialists: www.LLS.org/IRC
Assist through treatment, financial & social challenges, and give accurate treatment and support information. HCPs can also order free materials to distribute to patients.
Clinical Trial Support Center: www.LLS.org/CTSC
Patients & caregivers work one-on-one with an LLS Clinical Trial Nurse Navigator who will help find clinical trials and personally assist throughout the clinical trial process, providing an additional resource to the HCP team.
- Phone: (800) 955-4572, M-F, 9 am to 9 pm ET
- Email: infocenter@LLS.org
Live chat: www.LLS.org/InformationSpecialists
If you have any questions, please contact us at ProfEducation@LLS.org or call our Information Resource staff at 800-955-4572.